GlaxoSmithKline (GB:GSK)
LSE:GSK
GSK Stock Chart & Stats
2096.00 p
-0.50 p(-0.04%)
At close: 4:00 PM EST
2096.00 p
-0.50 p(-0.04%)
Day’s Range― - ―
52-Week Range1,242.50 p - 2,282.00 p
Previous CloseN/A
Volume367.08K
Average Volume (3M)8.54M
Market Cap
£83.77B
Enterprise Value99.26B
Total Cash (Recent Filing)£3.41B
Total Debt (Recent Filing)£17.72B
Price to Earnings (P/E)12.9
Beta1.08
Next Earnings
Apr 29, 2026EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend Yield3.29%
Share Statistics
EPS (TTM)0.26
Shares Outstanding4,059,387,200
10 Day Avg. Volume6,837,178
30 Day Avg. Volume8,542,213
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)4.51
Price to Sales (P/S)2.26
P/FCF Ratio12.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£2,019.00Price Target Upside-3.67% Downside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)1.79
Revenue Forecast (FY)£33.87B
Bulls Say, Bears Say
Bulls Say
Physician AdoptionAnalyst notes community hematology/oncology doctors expect meaningful use of Blenrep in later-line settings and some uptake in earlier-line settings, supporting higher peak sales potential.
Pipeline And Product LaunchesAnalyst highlights antibody-drug conjugate programs alongside respiratory and inflammation candidates and planned business development that could drive specialty sales and help offset revenue declines from the HIV franchise.
Safety And AccessAnalyst reports most physicians view ocular toxicity from Blenrep as only a slight concern and consider REMS requirements moderately inconvenient, implying safety and access are unlikely to be major adoption barriers.
Bears Say
Financial And Execution RiskAnalyst warns that high indebtedness combined with reliance on multiple late-stage clinical readouts increases execution and funding risk, while company guidance factors foreign exchange headwinds and implies margin pressure.
HIV Program Timeline UncertaintyAnalyst cautions that uncertainty around late-stage HIV program timelines and ongoing commercial debates for certain specialty drugs constrains visibility on growth and valuation upside.
Launch And Real-world Uptake RiskAnalyst applies a substantial risk adjustment to Blenrep sales forecasts pending clearer evidence on launch trajectory and real-world uptake, indicating material uncertainty around initial commercialization.
GlaxoSmithKline News
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1242.50 p and its highest was 2282.00 p in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is £83.77B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Apr 29, 2026 which is in 20 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Feb 04, 2026. The company reported 0.255 p earnings per share for the quarter, beating the consensus estimate of 0.238 p by 0.017 p.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Overvalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Quarterly dividend of 16 p which represents an annual dividend yield of 3.29%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 0.44.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,059,387,200 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of 0.255 p in its last earnings report, beating expectations of 0.238 p. Following the earnings report the stock price went up 6.913%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GB:GSK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GlaxoSmithKline Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
£2,019.00 (-3.67% Downside)
£2,019.00 (-3.67% Downside)
Insider Transactions
Sold Shares
Worth £22.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.62%
12-Months-Change
Fundamentals
Return on Equity
37.19%
Trailing 12-Months
Asset Growth
2.78%
Trailing 12-Months
Company Description
GlaxoSmithKline
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
GSK Stock 12 Month Forecast
Average Price Target
2,019.00 p
▼(-3.67% Downside)
Technical Analysis
AstraZeneca
―
Hikma Pharmaceuticals
―
Smith & Nephew
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Haleon PLC
―
Options Prices
Currently, No data available
---